Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
OwnerBernhard GÜNTHER, Frank LÖSCHER +1inventors
InventorsBernhard GÜNTHER, Frank LÖSCHER, Kirsten EICKHOFF
Life of this patent
Estimating the term…
Abstract
The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein—the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and—the composition is administered to the eye of a subject; and—the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.
Claims15
A pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein
- the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane;
- and
- the composition is administered to the eye of a subject;
- and
- the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 μg.
The composition for use according to any one of the preceding claims, wherein the composition further comprises a solubilising agent.
The composition for use according to any one of the preceding claims, wherein the composition is substantially free of water and of a preservative.
The composition for use according to any one of the preceding claims, wherein the composition target dose volume per eye is from about 8 to 15 μl, preferably from about 10 to 12 μl.
The composition for use according to any one of the preceding claims, wherein the composition comprises about 0.005 to 0.015% (w/v), preferably about 0.008 to 0.012% (w/v) latanoprost.
The composition for use according to any one of the preceding claims, wherein the amount of latanoprost administered in a single dose per eye is in the range of from about 1.0 to 1.2 μg.
The composition for use according to any one of the preceding claims, wherein the composition comprises about 0.01% (w/v) latanoprost, and wherein the latanoprost administered in a single dose per eye is about 1.1 μg and wherein the composition target dose volume per eye is about 11 μl.
The pharmaceutical composition for use according to any one of the preceding claims, wherein the composition comprises latanoprost dissolved in a liquid vehicle essentially consisting of at least 99% (w/w) of 1-perfluorobutyl-pentane (CF3(CF2)3—(CH2)4CH3 (F4H5)) or 1-perfluorohexyl-octane (CF3(CF2)5—(CH2)7CH3 (F6H8)) and up to 1% (w/w) ethanol, with respect to the total weight of the liquid vehicle.
The composition for use according to any one of the preceding claims, wherein the composition is administered once daily.
A kit comprising a pharmaceutical composition for use according to any one of the preceding claims, wherein the kit comprises a container for holding the pharmaceutical composition and a drop dispenser for administering the composition.
Dependencies are inferred from the claim text.